Phospho-PTK2B (Y881) Antibody

What is PTK2B and why is phosphorylation at Y881 important?

PTK2B (Protein Tyrosine Kinase 2 Beta), also known as PYK2 (Proline-rich Tyrosine Kinase 2), FAK2 (Focal Adhesion Kinase 2), or RAFTK (Related Adhesion Focal Tyrosine Kinase), is a non-receptor tyrosine kinase primarily expressed in the central nervous system, particularly in the amygdala and hippocampus, as well as in spleen and lymphocytes . This calcium-dependent tyrosine kinase plays crucial roles in multiple signaling pathways including calcium-induced regulation of ion channels, MAP kinase pathway activation, and cell adhesion mechanisms .

Phosphorylation at tyrosine 881 (Y881) represents a critical post-translational modification that creates binding sites for specific signal transduction proteins. When phosphorylated at Y881, PTK2B can recruit the adaptor protein Grb2 and the tyrosine kinase Abl . This recruitment initiates downstream signaling cascades that regulate various cellular processes including neuronal plasticity and immune cell function. The Y881 phosphorylation site is located in the amino acid region 847-896 of the human PTK2B protein .

How does PTK2B Y881 phosphorylation differ from phosphorylation at other sites like Y580 or Y402?

PTK2B contains multiple phosphorylation sites that serve distinct functions in signal transduction pathways. While Y881 phosphorylation primarily facilitates recruitment of Grb2 and Abl , phosphorylation at Y402 creates binding sites for Src Family Kinases (SFKs) through their SH2 domains, establishing a positive feedforward loop between PTK2B and SFKs . Phosphorylation at Y580, along with Y579, occurs in the activation loop and enhances the enzyme's kinase activity .

These site-specific phosphorylation events can occur independently or sequentially, creating a complex regulatory system. For example, SFKs can phosphorylate Y402 directly, which may be required for subsequent autophosphorylation of PTK2B in certain cellular contexts . The temporal and spatial regulation of these different phosphorylation events creates a sophisticated signaling network that responds to various cellular stimuli with appropriate biological outputs.

What is the relationship between PTK2B and Alzheimer's disease research?

The PTK2B gene has been identified as a risk factor for late-onset Alzheimer's disease through genome-wide association studies . Research suggests that PTK2B may contribute to Alzheimer's pathophysiology through complex mechanisms involving neuronal signaling pathways and synaptic function.

PTK2B is highly expressed in the hippocampus and amygdala , brain regions critically affected in Alzheimer's disease. As a non-receptor tyrosine kinase involved in calcium signaling and MAP kinase pathway activation, dysregulation of PTK2B phosphorylation could potentially disrupt neuronal homeostasis, synaptic plasticity, and memory formation. Investigating PTK2B phosphorylation patterns, including at the Y881 site, may provide insights into the molecular mechanisms underlying Alzheimer's disease progression and potential therapeutic targets.

What applications are phospho-PTK2B (Y881) antibodies validated for?

Phospho-PTK2B (Y881) antibodies have been validated for multiple research applications, offering versatility in studying this specific phosphorylation event across different experimental settings. The table below summarizes the validated applications and typical working dilutions based on the available antibody products:

When designing experiments, it's essential to optimize these dilutions for specific experimental conditions and sample types. The antibodies typically show reactivity with human, mouse, and rat samples, making them suitable for comparative studies across these species .

How should phospho-PTK2B (Y881) antibodies be validated before use in critical experiments?

Proper validation of phospho-specific antibodies is crucial for generating reliable and reproducible results. A comprehensive validation approach for phospho-PTK2B (Y881) antibodies should include:

• Phospho-specificity testing: Compare antibody reactivity with samples containing phosphorylated versus dephosphorylated PTK2B. This can be achieved by treating samples with phosphatase enzymes or using blocking experiments with phospho-peptides. Several manufacturers demonstrate this validation by showing blocked reactivity when the antibody is pre-incubated with the phospho-peptide immunogen .

• Signal blocking confirmation: Verify that the detected signal can be specifically blocked by the phosphopeptide used as the immunogen. This confirms the phospho-specificity of the antibody's binding characteristics .

• Cross-reactivity assessment: Test the antibody against closely related phosphorylation sites or proteins to ensure it specifically recognizes PTK2B phosphorylated at Y881 without detecting other phosphotyrosine sites or proteins .

• Positive and negative controls: Include appropriate controls in experiments, such as samples known to contain high levels of phosphorylated PTK2B (Y881) and samples where this phosphorylation is expected to be absent or reduced.

• Multiple detection methods: When possible, confirm findings using alternative techniques (e.g., mass spectrometry) to verify the presence and abundance of the specific phosphorylation event.

Thorough validation ensures that experimental results accurately reflect the biological phenomenon under investigation rather than artifacts or non-specific interactions.

What are the best sample preparation methods to preserve PTK2B phosphorylation for antibody detection?

Preserving protein phosphorylation during sample preparation is critical for obtaining accurate results with phospho-specific antibodies. For optimal detection of phosphorylated PTK2B at Y881:

• Rapid sample collection and processing: Minimize the time between tissue/cell collection and protein extraction to prevent dephosphorylation by endogenous phosphatases.

• Phosphatase inhibitors: Include a comprehensive phosphatase inhibitor cocktail in all buffers used during sample preparation. This should include inhibitors of serine/threonine phosphatases (e.g., sodium fluoride, β-glycerophosphate) and tyrosine phosphatases (e.g., sodium orthovanadate, sodium pyrophosphate).

• Protease inhibitors: Add protease inhibitors to prevent degradation of PTK2B, which has a molecular weight of approximately 116 kDa .

• Temperature control: Perform all sample preparation steps at 4°C to reduce enzyme activity and maintain phosphorylation states.

• Lysis buffer optimization: Use lysis buffers containing detergents that effectively solubilize membrane-associated proteins, as PTK2B can localize to cell membranes, focal adhesions, and the perinuclear region .

• Tissue-specific considerations: For brain tissue, which expresses high levels of PTK2B, particularly in the amygdala and hippocampus , rapid extraction is especially important due to high phosphatase activity in neural tissues.

• Fixation for IHC applications: For immunohistochemistry, use fixation protocols that preserve phosphoepitopes, such as paraformaldehyde fixation followed by careful antigen retrieval. High-pressure and temperature Tris-EDTA (pH 8.0) has been successfully used for antigen retrieval in IHC applications .

How can I design experiments to study the activation dynamics of PTK2B phosphorylation at Y881?

Designing robust experiments to capture the temporal and spatial dynamics of PTK2B Y881 phosphorylation requires careful consideration of multiple factors:

• Time-course experiments: To capture the dynamics of phosphorylation, design time-course experiments following stimulus application. For calcium-dependent activation of PTK2B, collect samples at multiple time points (e.g., 0, 1, 5, 15, 30, 60 minutes) after stimulation with calcium ionophores or physiological stimuli that increase intracellular calcium.

• Stimulus selection: Choose stimuli relevant to the biological context being studied. For neuronal systems, consider glutamate receptor agonists, depolarizing stimuli, or physiological activity patterns. For immune cells, appropriate receptor ligands or cellular activation protocols should be used.

• Inhibitor studies: Include specific kinase inhibitors (e.g., SFK inhibitors) to dissect the signaling pathways involved in Y881 phosphorylation. This helps establish whether Y881 phosphorylation is a direct or indirect result of specific upstream signals.

• Subcellular fractionation: Combine cellular fractionation with phospho-specific detection to track the subcellular localization of phosphorylated PTK2B. This is particularly important given that PTK2B can localize to various cellular compartments including the cytoplasm, cell membrane, focal adhesions, and nucleus .

• Single-cell analysis: When possible, employ single-cell techniques such as immunofluorescence or phospho-flow cytometry to capture cell-to-cell variability in phosphorylation responses.

• Quantification methods: Use appropriate quantification methods such as densitometry for Western blots, with normalization to total PTK2B levels to account for variations in protein expression.

What controls should be included when performing phospho-PTK2B (Y881) Western blots?

Robust controls are essential for accurate interpretation of phospho-PTK2B (Y881) Western blot results:

• Phospho-specificity control: Include a lane where the antibody has been pre-incubated with the phosphopeptide immunogen to demonstrate signal specificity .

• Total PTK2B detection: Probe a parallel blot (or strip and reprobe) with an antibody recognizing total PTK2B regardless of phosphorylation status. This allows normalization of phospho-signal to total protein levels.

• Positive control: Include a sample known to contain phosphorylated PTK2B (Y881), such as brain tissue extracts or stimulated cells known to activate PTK2B signaling.

• Negative control: Include samples where PTK2B Y881 phosphorylation should be minimal, such as serum-starved cells or tissues from PTK2B knockout animals (if available).

• Phosphatase treatment control: Treat a duplicate sample with lambda phosphatase to demonstrate that the signal depends on protein phosphorylation.

• Loading control: Include detection of a housekeeping protein (e.g., GAPDH, β-actin) to ensure equal loading across lanes.

• Molecular weight markers: Include appropriate molecular weight markers to confirm the detected band is at the expected size (~116 kDa for PTK2B) .

• Antibody validation control: When first establishing the assay, consider including samples from cell lines with PTK2B knockdown or knockout to verify antibody specificity.

How can I quantitatively assess changes in PTK2B Y881 phosphorylation in response to stimuli?

Quantitative assessment of PTK2B Y881 phosphorylation requires appropriate experimental design and analytical approaches:

• Normalization strategy: Always normalize phospho-PTK2B (Y881) signals to total PTK2B levels to account for variations in protein expression across samples. This provides a measure of the proportion of PTK2B that is phosphorylated rather than absolute levels.

• Relative quantification: Express phosphorylation levels relative to a control condition (e.g., unstimulated cells) to determine fold-changes in response to experimental treatments.

• Multiple technical replicates: Perform at least three technical replicates of Western blots to account for technical variability in the assay.

• Multiple biological replicates: Include independent biological replicates (different cell preparations or animals) to ensure reproducibility and account for biological variability.

• Linear dynamic range: Ensure detection is within the linear dynamic range of the detection method by performing dilution series experiments.

• Statistical analysis: Apply appropriate statistical tests based on experimental design, such as t-tests for simple comparisons or ANOVA for multiple conditions, with post-hoc tests as needed.

• Complementary approaches: Consider complementing Western blot analysis with other quantitative methods such as ELISA or mass spectrometry-based phosphoproteomics for more precise quantification.

How does PTK2B Y881 phosphorylation interact with other signaling pathways in neuronal cells?

PTK2B Y881 phosphorylation represents an important node in complex neuronal signaling networks. Current research indicates several key interactions:

• Grb2-Ras-MAPK pathway: Phosphorylated Y881 creates a binding site for the adaptor protein Grb2 , which can recruit SOS and activate the Ras-MAPK pathway. This pathway regulates gene expression programs involved in neuronal plasticity and survival.

• Abl tyrosine kinase signaling: Phospho-Y881 can recruit the Abl tyrosine kinase , which may regulate cytoskeletal dynamics important for neuronal morphology and synaptic function.

• Cross-talk with calcium signaling: As a calcium-dependent kinase, PTK2B integrates calcium signals with tyrosine phosphorylation cascades. Y881 phosphorylation may function as a temporal integrator of calcium transients in neurons.

• Src family kinase (SFK) interactions: There exists a complex interplay between PTK2B and SFKs, with PTK2B Y402 phosphorylation recruiting SFKs, which can then phosphorylate other tyrosine residues on PTK2B including potentially Y881 . This creates feed-forward amplification loops in signaling.

• NMDA receptor modulation: In the brain, PTK2B can modulate NMDA receptor function, affecting synaptic plasticity mechanisms underlying learning and memory. Y881 phosphorylation may play a role in this regulation.

Understanding these complex interactions requires sophisticated experimental approaches, including pathway inhibition studies, temporal analysis of sequential phosphorylation events, and systems biology approaches to model the integrated signaling network.

What are the most effective methods to study the functional consequences of PTK2B Y881 phosphorylation?

Investigating the functional impact of PTK2B Y881 phosphorylation requires a multi-faceted approach:

How can PTK2B Y881 phosphorylation be analyzed in the context of Alzheimer's disease research?

Given the association between PTK2B and Alzheimer's disease risk , several approaches can be employed to investigate the relationship between Y881 phosphorylation and disease mechanisms:

• Human tissue studies: Compare PTK2B Y881 phosphorylation levels in post-mortem brain tissue from Alzheimer's patients versus age-matched controls, with particular focus on the hippocampus and amygdala where PTK2B is highly expressed .

• Animal models: Analyze Y881 phosphorylation in rodent models of Alzheimer's disease at different disease stages to identify temporal patterns of altered phosphorylation.

• Genetic interaction studies: Investigate how Alzheimer's risk variants in the PTK2B gene affect Y881 phosphorylation and downstream signaling, potentially using induced pluripotent stem cells (iPSCs) derived from carriers and non-carriers of risk alleles.

• Amyloid-β interaction: Examine whether amyloid-β exposure affects PTK2B Y881 phosphorylation in primary neuronal cultures, potentially linking amyloid pathology to altered PTK2B signaling.

• Tau phosphorylation relationship: Investigate potential connections between PTK2B Y881 phosphorylation and tau hyperphosphorylation, a key feature of Alzheimer's pathology.

• Therapeutic intervention testing: Assess whether experimental Alzheimer's therapeutics affect PTK2B Y881 phosphorylation as part of their mechanism of action or as biomarkers of target engagement.

• Single-cell analysis: Apply single-cell phosphoproteomics or multiplex immunofluorescence imaging to identify cell type-specific alterations in PTK2B Y881 phosphorylation in the context of Alzheimer's disease.

What are common challenges when detecting phospho-PTK2B (Y881) and how can they be addressed?

Researchers may encounter several technical challenges when working with phospho-PTK2B (Y881) antibodies:

• Low signal intensity: PTK2B phosphorylation may be transient or occur at low stoichiometry. To address this:

  • Optimize stimulation conditions to maximize phosphorylation

  • Ensure complete phosphatase inhibition during sample preparation

  • Consider signal amplification methods such as enhanced chemiluminescence substrates

  • Enrich for phosphoproteins prior to analysis using phosphotyrosine immunoprecipitation

• High background: Non-specific binding can complicate interpretation. To reduce background:

  • Optimize blocking conditions (type of blocking agent, concentration, time)

  • Increase washing stringency and duration

  • Titrate primary antibody concentration to find optimal signal-to-noise ratio

  • Pre-adsorb antibody with non-specific proteins if background persists

• Cross-reactivity: Antibodies may detect other phosphotyrosine-containing proteins. To address this:

  • Always verify the molecular weight of detected bands (~116 kDa for PTK2B)

  • Perform phosphopeptide competition assays to confirm specificity

  • Consider immunoprecipitation of PTK2B followed by phospho-detection

• Sample degradation: Phosphorylation sites are sensitive to post-collection dephosphorylation. To prevent this:

  • Process samples rapidly

  • Use strong phosphatase inhibitor cocktails

  • Consider heat-stabilization methods for tissue samples

• Inconsistent results across experiments: Variability can arise from multiple sources. To improve consistency:

  • Standardize all aspects of sample preparation

  • Use internal controls across experiments

  • Maintain consistent exposure times when imaging Western blots

  • Consider using phospho-flow cytometry for more quantitative single-cell analysis

How can I differentiate between specific phospho-PTK2B (Y881) signal and artifacts?

Distinguishing genuine phospho-PTK2B (Y881) signal from artifacts requires systematic controls and validation:

• Phosphopeptide competition: Pre-incubate the antibody with the phosphopeptide immunogen before application to samples. A specific signal should be blocked, while non-specific signals will remain .

• Non-phosphopeptide competition: As a control for the above, pre-incubate with the corresponding non-phosphorylated peptide. This should not affect specific phospho-PTK2B detection.

• Molecular weight verification: Ensure the detected band appears at the correct molecular weight (~116 kDa) . Multiple bands or bands at unexpected molecular weights may indicate non-specific binding or degradation products.

• Phosphatase treatment: Treat a portion of your sample with lambda phosphatase prior to analysis. This should eliminate phospho-specific signals while leaving non-specific signals intact.

• Stimulus-response validation: Verify that known stimuli that activate PTK2B (e.g., calcium influx) increase the phospho-Y881 signal, while inhibitors of upstream kinases decrease the signal.

• Multiple detection methods: When possible, confirm findings using alternative techniques such as mass spectrometry or ELISA to corroborate Western blot results.

• Genetic controls: If available, samples from PTK2B knockout or knockdown models should show absence of specific signal while maintaining any non-specific bands.

What are best practices for reproducible quantification of PTK2B Y881 phosphorylation across different experimental systems?

Ensuring reproducible quantification of PTK2B Y881 phosphorylation requires standardized approaches:

• Protocol standardization: Develop and strictly adhere to standardized protocols for:

  • Sample collection and preservation

  • Protein extraction and quantification

  • Electrophoresis and transfer conditions

  • Antibody incubation parameters

  • Detection and imaging settings

• Normalization strategy: Always normalize phospho-signals to total PTK2B levels measured in the same experiment, preferably on parallel blots rather than through stripping and reprobing to avoid signal loss.

• Technical replicates: Include technical replicates within each experiment to assess method variability.

• Biological replicates: Perform independent biological replicates (different cell preparations or animals) to ensure biological reproducibility.

• Standard curves: When possible, include standard curves using recombinant phosphorylated proteins or phosphopeptides for absolute quantification.

• Reference samples: Include common reference samples across different experimental batches to allow for inter-experimental normalization.

• Blinding procedures: Implement blinding during sample processing and analysis to prevent unconscious bias in quantification.

• Image acquisition standardization: Establish consistent image acquisition settings, ensuring signals are within the linear dynamic range of detection.

• Data reporting standards: Report all relevant experimental details, including antibody source, catalog number, and dilution, as well as quantification methods and statistical analyses performed.

• Data sharing: Consider sharing raw data and detailed protocols through repositories to enhance reproducibility across laboratories.

What emerging technologies might enhance the study of PTK2B Y881 phosphorylation dynamics?

Several cutting-edge technologies hold promise for advancing our understanding of PTK2B Y881 phosphorylation:

• Proximity labeling proteomics: Techniques such as BioID or APEX2 fused to PTK2B could identify proteins that interact with PTK2B specifically when Y881 is phosphorylated, providing insights into context-specific signaling complexes.

• Phospho-specific biosensors: Development of FRET-based biosensors for Y881 phosphorylation would enable real-time monitoring of PTK2B activation dynamics in living cells with high spatial and temporal resolution.

• Mass spectrometry innovations: Advanced mass spectrometry approaches, including targeted parallel reaction monitoring (PRM) and data-independent acquisition (DIA), can provide more sensitive and quantitative assessment of PTK2B phosphorylation stoichiometry across multiple sites simultaneously.

• Single-cell phosphoproteomics: Emerging single-cell phosphoproteomic technologies could reveal cell-to-cell heterogeneity in PTK2B phosphorylation within complex tissues like the brain.

• Spatial transcriptomics integration: Combining phosphorylation analysis with spatial transcriptomics could reveal how PTK2B Y881 phosphorylation correlates with gene expression patterns in specific anatomical contexts.

• Cryo-electron microscopy: Structural studies of PTK2B in different phosphorylation states could reveal how Y881 phosphorylation affects protein conformation and interaction capabilities.

• Proteome-wide tyrosine phosphorylation arrays: High-throughput approaches similar to those used in the CPTAC project could be applied to systematically map kinase-substrate relationships involving PTK2B.

How might understanding PTK2B Y881 phosphorylation contribute to therapeutic development for neurological disorders?

The association between PTK2B and Alzheimer's disease risk suggests several potential therapeutic applications:

• Target validation: Detailed characterization of how Y881 phosphorylation affects neuronal function and viability could validate PTK2B as a therapeutic target for Alzheimer's disease or other neurological conditions.

• Biomarker development: Changes in PTK2B Y881 phosphorylation might serve as biomarkers for disease progression or treatment response in neurological disorders, potentially detectable in cerebrospinal fluid or through neuroimaging approaches targeting phosphorylation events.

• Drug discovery strategies: Understanding the structural consequences of Y881 phosphorylation could guide the development of:

  • Small molecule inhibitors that specifically block Y881 phosphorylation

  • Protein-protein interaction inhibitors that prevent phospho-Y881 from recruiting downstream effectors

  • Allosteric modulators that stabilize specific PTK2B conformational states

• Pathway-based interventions: Mapping how Y881 phosphorylation interfaces with other signaling pathways involved in neurodegeneration could identify combination therapy approaches or reveal more druggable targets downstream of PTK2B.

• Personalized medicine approaches: Genetic variations in PTK2B and associated pathways could inform patient stratification for clinical trials and eventually guide treatment selection based on individual molecular profiles.

• Gene therapy potential: Advanced gene therapy approaches could target the expression or function of PTK2B in specific brain regions most vulnerable to neurodegeneration.